Race as an Independent Risk Factor for Breast Cancer Survival: Breast Cancer Outcomes From the Medical College of Georgia Tumor Registry

被引:18
作者
Barcenas, Carlos H. [1 ]
Wells, Jeremy [1 ]
Chong, Daniel [1 ]
French, John [1 ]
Looney, Stephen W. [2 ]
Samuel, Thomas A. [1 ]
机构
[1] Med Coll Georgia, Dept Med, Hematol Oncol Sect, Augusta, GA 30912 USA
[2] Med Coll Georgia, Dept Biostat, Augusta, GA 30912 USA
关键词
Hormone receptor status; Hormone therapy; Prognostic factors; AFRICAN-AMERICAN; SOCIOECONOMIC-STATUS; RACIAL-DIFFERENCES; CLINICAL-OUTCOMES; HOT FLASHES; ETHNICITY; TAMOXIFEN; WOMEN; CARCINOMA;
D O I
10.3816/CBC.2010.n.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. Patients and Methods: Data were obtained from the Medical College of Georgia Tumor Registry. Cases included those diagnosed between 1990 and 2005. We analyzed race, stage, age of diagnosis, and treatment received: chemotherapy, radiation, surgery, and hormonal therapy. A Cox proportional hazards model was used to determine differences in OS. Results: Compared with 670 white women, 489 black women were more likely to be younger, have later-stage disease at diagnosis, and were less likely to have received hormonal therapy. Both groups received similar rates of radiation, surgery, and chemotherapy. Black women had significantly poorer OS (adjusted hazard ratio, 1.35; 95% CI, 1.12-1.63). White women had a 5-year OS of 54% compared with 45% in black women (P = .0031). Having received radiation, surgery, or chemotherapy was not associated with OS. White women were more likely to have received hormonal therapy, which had a significant protective effect. However, a stratified analysis (between those who received hormonal therapy and those who did not) showed similar results, whereas black women experienced poorer OS in both strata. Conclusion: Black women with breast cancer had a significantly poorer OS compared with white women. White women received more hormonal therapy, which had a protective effect. There were no differences in treatment received regarding radiation, surgery, or chemotherapy, and these treatments were not associated with OS. The reasons for racial disparities in breast cancer OS remain complex.
引用
收藏
页码:59 / 63
页数:5
相关论文
共 19 条
[1]  
[Anonymous], CANC STAT REV 1975 2
[2]  
[Anonymous], 2007, CANC FACTS FIGURES A, P1
[3]   Effect of screening and adjuvant therapy on mortality from breast cancer [J].
Berry, DA ;
Cronin, KA ;
Plevritis, SK ;
Fryback, DG ;
Clarke, L ;
Zelen, M ;
Mandelblatt, JS ;
Yakovlev, AY ;
Habbema, JDF ;
Feuer, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792
[4]  
Bradley CJ, 2002, J NATL CANCER I, V94, P490
[5]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[6]   Ethnicity and breast cancer: Factors influencing differences in incidence and outcome [J].
Chlebowski, RT ;
Chen, Z ;
Anderson, GL ;
Rohan, T ;
Aragaki, A ;
Lane, D ;
Dolan, NC ;
Paskett, ED ;
McTiernan, A ;
Hubbell, FA ;
Adams-Campbell, LL ;
Prentice, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) :439-448
[7]   Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes [J].
Dawood, Shaheenah ;
Broglio, Kristine ;
Kau, Shu-Wan ;
Green, Marjorie C. ;
Giordano, Sharon H. ;
Meric-Bernstam, Funda ;
Buchholz, Thomas A. ;
Albarracin, Constance ;
Yang, Wei T. ;
Hennessy, Bryan T. J. ;
Hortobagyi, Gabriel N. ;
Gonzalez-Angulo, Ana Maria .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) :220-226
[8]   The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen [J].
Goetz, Matthew P. ;
Knox, Stacey K. ;
Suman, Vera J. ;
Rae, James M. ;
Safgren, Stephanie L. ;
Ames, Matthew M. ;
Visscher, Daniel W. ;
Reynolds, Carol ;
Couch, Fergus J. ;
Lingle, Wilma L. ;
Weinshilboum, Richard M. ;
Fritcher, Emily G. Barr ;
Nibbe, Andrea M. ;
Desta, Zeruesenay ;
Nguyen, Anne ;
Flockhart, David A. ;
Perez, Edith A. ;
Ingle, James N. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) :113-121
[9]   Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes [J].
Goetz, MP ;
Rae, JM ;
Suman, VJ ;
Safgren, SL ;
Ames, MM ;
Visscher, DW ;
Reynolds, C ;
Couch, FJ ;
Lingle, WL ;
Flockhart, DA ;
Desta, Z ;
Perez, EA ;
Ingle, JN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9312-9318
[10]   Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897 [J].
Hershman, Dawn L. ;
Unger, Joseph M. ;
Barlow, William E. ;
Hutchins, Laura F. ;
Martino, Silvana ;
Osborne, C. Kent ;
Livingston, Robert B. ;
Albain, Kathy S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2157-2162